About human tumor antigens to be used in immunotherapy

Seminars in Immunology

Volumn 20, Issue 5, 2008, Pages 301-307

  Lucas, S ^a   Coulie, P G ^a  

^a DE DUVE INSTITUTE   (Belgium)

Author keywords

Antigen; Immunotherapy; Vaccination

Indexed keywords

DIFFERENTIATION ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 3 A1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; BREAST CANCER; CANCER IMMUNOTHERAPY; COLON CARCINOMA; COLON TUMOR; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LUNG CARCINOMA; MELANOMA; NEUROBLASTOMA; NONHUMAN; OVARY CARCINOMA; POINT MUTATION; PROSTATE CARCINOMA; REVIEW; SOMATIC MUTATION; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA;

ANTIGENS, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MUTATION; NEOPLASMS;

EID: 55549094085     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2008.02.001     Document Type: Review

References (82)

1. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
2. Van den Eynde B, van der Bruggen P. Peptide database of T-cell defined tumor antigens. Updated in March 2007:URL: http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm.
3. Boon T., and van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 183 (1996) 725-729
4. Lonchay C., van der Bruggen P., Connerotte T., Hanagiri T., Coulie P., Colau D., et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 101 (2004) 14631-14638
5. Sugaya M., Takenoyama M., Osaki T., Yasuda M., Nagashima A., Sugio K., et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest 122 (2002) 282-288
6. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269 (1995) 1281-1284
7. (+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 64 (2004) 1595-1599
8. + T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 72 (1997) 784-790
9. Linard B., Bézieau S., Benlalam H., Labarrière N., Guilloux Y., Diez E., et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 168 (2002) 4802-4808
10. Bielas J.H., Loeb K.R., Rubin B.P., True L.D., and Loeb L.A. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 103 (2006) 18238-18242
11. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
12. Parmiani G., De Filippo A., Novellino L., and Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178 (2007) 1975-1979
13. Chang A.E., Redman B.G., Whitfield J.R., Nickoloff B.J., Braun T.M., Lee P.P., et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8 (2002) 1021-1032
14. Zhou X., Jun D.Y., Thomas A.M., Huang X., Huang L.Q., Mautner J., et al. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res 65 (2005) 1079-1088
15. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20 (2002) 4169-4180
16. Haas Jr. G.G., D'Cruz O.J., and De Bault L.E. Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. Am J Reprod Immunol Microbiol 18 (1988) 47-51
17. Fiszer D., and Kurpisz M. Major histocompatibility complex expression on human, male germ cells: a review. Am J Reprod Immunol 40 (1998) 172-176
18. De Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P., De Smet C., et al. Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics 40 (1994) 360-369
19. Chomez P., De Backer O., Bertrand M., De Plaen E., Boon T., and Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61 (2001) 5544-5551
20. Chen Y.-T., Scanlan M.J., Sahin U., Türeci O., Gure A.O., Tsang S., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94 (1997) 1914-1918
21. Lethé B., Lucas S., Michaux L., De Smet C., Godelaine D., Serrano A., et al. LAGE-1, a new gene with tumor specificity. Int J Cancer 76 (1998) 903-908
22. Gure A.O., Wei I.J., Old L.J., and Chen Y.T. The SSX gene family: characterization of 9 complete genes. Int J Cancer 101 (2002) 448-453
23. De Smet C., Lurquin C., Lethé B., Martelange V., and Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 19 (1999) 7327-7335
24. De Smet C., De Backer O., Faraoni I., Lurquin C., Brasseur F., and Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA 93 (1996) 7149-7153
25. Gotter J., Brors B., Hergenhahn M., and Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 199 (2004) 155-166
26. Derbinski J., Schulte A., Kyewski B., and Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2 (2001) 1032-1039
27. Hanagiri T., van Baren N., Neyns B., Boon T., and Coulie P.G. Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1. Cancer Immunol Immunother 55 (2006) 178-184
28. Godelaine D., Carrasco J., Lucas S., Karanikas V., Schuler-Thurner B., Coulie P.G., et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171 (2003) 4893-4897
29. Karanikas V., Lurquin C., Colau D., van Baren N., De Smet C., Lethé B., et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 171 (2003) 4898-4904
30. Anichini A., Maccalli C., Mortarini R., Salvi S., Mazzocchi A., Squarcina P., et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 177 (1993) 989-998
31. Berger T.G., Haendle I., Schrama D., Luftl M., Bauer N., Pedersen L.O., et al. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int J Cancer 111 (2004) 229-237
32. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., Barnd D.L., Eastham S., Galavotti H., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21 (2003) 4016-4026
33. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., et al. Melanocyte-destruction after antigen-specific immunotherapy of melanoma: direct evidence of T-cell mediated vitiligo. J Exp Med 192 (2000) 1637-1643
34. Powell Jr. D.J., Dudley M.E., Hogan K.A., Wunderlich J.R., and Rosenberg S.A. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177 (2006) 6527-6539
35. Le Gal F.A., Avril M.F., Bosq J., Lefebvre P., Deschemin J.C., Andrieu M., et al. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol 117 (2001) 1464-1470
36. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
37. Fisk B., Blevins T.L., Wharton J.T., and Ioannides C.G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocytes lines. J Exp Med 181 (1995) 2109-2117
38. Linehan D.C., Goedegebuure P.S., Peoples G.E., Rogers S.O., and Eberlein T.J. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155 (1995) 4486-4491
39. Yoshino I., Goedegebuure P.S., Peoples G.E., Parikh A.S., DiMaio J.M., Lyerly H.K., et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54 (1994) 3387-3390
40. Ikeda H., Lethé B., Lehmann F., Van Baren N., Baurain J.-F., De Smet C., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6 (1997) 199-208
41. Oberthuer A., Hero B., Spitz R., Berthold F., and Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10 (2004) 4307-4313
42. Van Baren N., Chambost H., Ferrant A., Michaux L., Ikeda H., Millard I., et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 102 (1998) 1376-1379
43. Pellat-Deceunynck C., Mellerin M.P., Labarriere N., Jego G., Moreau-Aubry A., Harousseau J.L., et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 30 (2000) 803-809
44. Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., and Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122 (2005) 835-847
45. Epping M.T., and Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 66 (2006) 10639-10642
46. Greiner J., Schmitt M., Li L., Giannopoulos K., Bosch K., Schmitt A., et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 108 (2006) 4109-4117
47. Griffioen M., Kessler J.H., Borghi M., van Soest R.A., van der Minne C.E., Nouta J., et al. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy. Clin Cancer Res 12 (2006) 3130-3136
48. Schroers R., Huang X.F., Hammer J., Zhang J., and Chen S.Y. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 62 (2002) 2600-2605
49. Vonderheide R.H., Hahn W.C., Schultze J.L., and Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytolytic T lymphocytes. Immunity 10 (1999) 673-679
50. Minev B., Hipp J., Firat H., Schmidt J.D., Langlade-Demoyen P., and Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97 (2000) 4796-4801
51. Vonderheide R.H., Domchek S.M., Schultze J.L., George D.J., Hoar K.M., Chen D.Y., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10 (2004) 828-839
52. Parkhurst M.R., Riley J.P., Igarashi T., Li Y., Robbins P.F., and Rosenberg S.A. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10 (2004) 4688-4698
53. Ayyoub M., Migliaccio M., Guillaume P., Lienard D., Cerottini J.C., Romero P., et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 31 (2001) 2642-2651
54. Inoue K., Ogawa H., Sonoda Y., Kimura T., Sakabe H., Oka Y., et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89 (1997) 1405-1412
55. Keilholz U., Menssen H.D., Gaiger A., Menke A., Oji Y., Oka Y., et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 19 (2005) 1318-1323
56. Asemissen A.M., Keilholz U., Tenzer S., Muller M., Walter S., Stevanovic S., et al. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res 12 (2006) 7476-7482
57. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101 (2004) 13885-13890
58. Weidanz J.A., Nguyen T., Woodburn T., Neethling F.A., Chiriva-Internati M., Hildebrand W.H., et al. Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol 177 (2006) 5088-5097
59. Lethé B., van der Bruggen P., Brasseur F., and Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific CTL. Melanoma Res 7 (1997) S83-S88
60. Serrano A., Lethé B., Delroisse J.-M., Lurquin C., De Plaen E., Brasseur F., et al. Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries. Int J Cancer 83 (1999) 664-669
61. So T., Hanagiri T., Chapiro J., Colau D., Brasseur F., Yasumoto K., et al. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. Cancer Immunol Immunother 56 (2007) 259-269
62. Purbhoo M.A., Sutton D.H., Brewer J.E., Mullings R.E., Hill M.E., Mahon T.M., et al. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol 176 (2006) 7308-7316
63. Denkberg G., Lev A., Eisenbach L., Benhar I., and Reiter Y. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J Immunol 171 (2003) 2197-2207
64. Chames P., Hufton S.E., Coulie P.G., Uchanska-Ziegler B., and Hoogenboom H.R. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc Natl Acad Sci USA 97 (2000) 7969-7974
65. Oosterwijk E., Ruiter D.J., Hoedemaeker P.J., Pauwels E.K.J., Jonas U., Zwartendijk J., et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38 (1986) 489-494
66. Grabmaier K., Vissers J.L.M., De Weijert M.C.A., Oosterwijk-Wakka J.C., Van Bokhoven A., Brakenhoff R.H., et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G 250. Int J Cancer 85 (2000) 865-870
67. McKiernan J.M., Buttyan R., Bander N.H., Stifelman M.D., Katz A.E., Chen M.-W., et al. Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res 57 (1997) 2362-2365
68. Opavsky R., Pastorekova S., Zelnik V., Gibadulinova A., Stanbridge E.J., Zavada J., et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33 (1996) 480-487
69. Vissers J.L.M., De Vries I.J.M., Schreurs M.W.J., Engelen L.P.H., Oosterwijk E., Figdor C.G., et al. The renal cell carcinoma-associated antigen G 250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59 (1999) 5554-5559
70. Vissers J.L., De Vries I.J., Engelen L.P., Scharenborg N.M., Molkenboer J., Figdor C.G., et al. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int J Cancer 100 (2002) 441-444
71. Su Z., Dannull J., Heiser A., Yancey D., Pruitt S., Madden J., et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63 (2003) 2127-2133
72. Weijtens M.E., Willemsen R.A., Valerio D., Stam K., and Bolhuis R.L. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 157 (1996) 836-843
73. Lamers C.H., Langeveld S.C., Groot-van Ruijven C.M., Debets R., Sleijfer S., and Gratama J.W. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother 56 (2007) 1875-1883
74. Lamers C.H., Sleijfer S., Vulto A.G., Kruit W.H., Kliffen M., Debets R., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24 (2006) e20-e22
75. Coulie P.G., and Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number?. Curr Opin Immunol 17 (2005) 320-325
76. Germeau C., Ma W., Schiavetti F., Lurquin C., Henry E., Vigneron N., et al. High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201 (2005) 241-248
77. Lurquin C., Lethé B., Corbière V., Théate I., van Baren N., Coulie P.G., et al. Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201 (2005) 249-257
78. Khong H.T., and Rosenberg S.A. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol 168 (2002) 951-956
79. Butterfield L.H., Ribas A., Dissette V.B., Amarnani S.N., Vu H.T., Oseguera D., et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9 (2003) 998-1008
80. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20 (2002) 2624-2632
81. Lally K.M., Mocellin S., Ohnmacht G.A., Nielsen M.B., Bettinotti M., Panelli M.C., et al. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer 93 (2001) 841-847
82. Vignard V., Lemercier B., Lim A., Pandolfino M.C., Guilloux Y., Khammari A., et al. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol 175 (2005) 4797-4805